Emcure Pharma to launch oral Covid-19 drug in a week Kumar Jeetendra | January 2, 2022 Emcure Pharmaceuticals Ltd (EPL) reported that it received an emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the introduction of Molnupiravir the oral anti-viral that is under investigation, to treat mild COVID-19. EPL plans to launch this drug with the name Lizuvira on India. Indian market. “As the need for …
Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu® (Molnupiravir 200 mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and who have high risk of progression of the disease including hospitalization or death. Kumar Jeetendra | December 28, 2021 Mumbai, India; December 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. …
New drug Molnupiravir can be the solution for our fight against COVID-19 Kumar Jeetendra | December 28, 2021 Mumbai, 28th December 2021: As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade …
Cipla Receives Final Approval for Lanreotide Injection Kumar Jeetendra | December 19, 2021 Mumbai, India, & New Jersey, USA: December 19, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”)and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), today announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The …
Cipla acquires stake in Clean Max Auriga Power LLP; progresses towards championing its ESG agenda Kumar Jeetendra | December 16, 2021 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has acquired up to 33% of partnership interest in Clean Max Auriga Power LLP (Limited Liability Partnership). This agreement is in line with the Company’s commitment to enhance the share of renewable power source in its operation and …
Inceptua receives approval of marketing authorization transfer of Apealea® (paclitaxel micellar) for the treatment of ovarian cancer Kumar Jeetendra | December 14, 2021 LUXEMBOURG – 14 December 2021 – Life Science Newswire – Inceptua Group – pharmaceutical company and service partner – today announces that the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the transfer of the marketing authorization for Apealea® (paclitaxel micellar) from Oasmia Pharmaceutical AB to Inceptua AB. …
Cipla launches initiative to improve access to nebulisers for acute asthma management in primary health care centres of rural India Kumar Jeetendra | December 10, 2021 Mumbai, 10th December 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced a first-of-its-kind initiative to improve access to nebulization therapy specifically for patients in the rural sections of the country. With Cipla’s unmatched presence across the care continuum and a wide range of drug-device combinations and treatments, the …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg. Kumar Jeetendra | December 8, 2021 8th December, 2021, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg. The tentatively approved ANDA is therapeutically equivalent …
Venair presented at interphex its new updated tubing range and products Kumar Jeetendra | December 7, 2021 Barcelona, Spain – 7 December 2021 – Life Science Newswire – During October 19-20-21 the Interphex international trade fair was held in New York, an event which stands out for the massive participation of the best companies in the pharmaceutical and biotechnology sector. They take advantage of this great occasion to present their new products …
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients Kumar Jeetendra | November 30, 2021 Bangalore, Nov. 30, 2021 – Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and …
Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Mupirocin Cream USP, 2%. Kumar Jeetendra | November 20, 2021 17th November 2021, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mupirocin Cream USP, 2%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), …
Cipla launches Spirofy®: Strengthens its lung leadership position by facilitating early diagnosis for COPD1 Kumar Jeetendra | November 17, 2021 Mumbai, India; November 17, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced the launch of Spirofy®, India’s first pneumotach based portable, wireless Spirometer, on World COPD Day. With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its …
